The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4

Akihito Kubo, Kazuhiko Nakagawa, Ravi K. Varma, Nicholas K. Conrad, Jin Quan Cheng, Wen Ching Lee, Joseph R. Testa, Bruce E. Johnson, Frederic J. Kaye, Michael J. Kelley

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Loss of p16 functional activity leading to disruption of the p16/cyclin- dependent kinase (CDK) 4:cyclin D/retinoblastoma pathway is the most common event in human tumorigenesis, suggesting that compounds with CDK4 kinase inhibitory activity may be useful to regulate cancer cell growth. To identify such inhibitors, the 60 cancer cell lines of the National Cancer Institute drug screen panel were examined for p16 alterations (biallelic deletion, intragenic mutations, or absent p16 protein), and the growth-inhibitory activity of more than 50,000 compounds against these 60 cell lines was compared with their p16 status. One compound, 3-amino thioacridone (3-ATA; NSC 680434), whose growth-inhibitory activity correlated with the p16 status of the cell lines had an IC50 of 3.1 μM in a CDK4 kinase assay. In addition, four compounds structurally related to 3-ATA inhibited CDK4 kinase with IC50s ranging from 0.2-2.0 μM. All five of these compounds were less potent inhibitors of cell division cycle 2 and CDK2 kinases, with IC50s 30- to 500-fold higher than that for CDK4. ATP competition experiments demonstrated a noncompetitive mode of inhibition for 3-ATA (K(i) = 5.5 μM) and a linear mixed mode for benzothiadiazine (NSC 645787; K(i) = 0.73 μM). We have successfully demonstrated a novel approach to identify specific CDK4 kinase inhibitors that may selectively induce growth inhibition of p16- altered tumors.

Original languageEnglish (US)
Pages (from-to)4279-4286
Number of pages8
JournalClinical Cancer Research
Volume5
Issue number12
StatePublished - Dec 1999

Fingerprint

Cyclin-Dependent Kinase 4
Tumor Cell Line
Phosphotransferases
Cell Line
Benzothiadiazines
Growth
Cyclin D
Neoplasms
National Cancer Institute (U.S.)
Retinoblastoma
Sequence Deletion
Inhibitory Concentration 50
Cell Cycle
Carcinogenesis
Adenosine Triphosphate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kubo, A., Nakagawa, K., Varma, R. K., Conrad, N. K., Cheng, J. Q., Lee, W. C., ... Kelley, M. J. (1999). The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clinical Cancer Research, 5(12), 4279-4286.

The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. / Kubo, Akihito; Nakagawa, Kazuhiko; Varma, Ravi K.; Conrad, Nicholas K.; Cheng, Jin Quan; Lee, Wen Ching; Testa, Joseph R.; Johnson, Bruce E.; Kaye, Frederic J.; Kelley, Michael J.

In: Clinical Cancer Research, Vol. 5, No. 12, 12.1999, p. 4279-4286.

Research output: Contribution to journalArticle

Kubo, A, Nakagawa, K, Varma, RK, Conrad, NK, Cheng, JQ, Lee, WC, Testa, JR, Johnson, BE, Kaye, FJ & Kelley, MJ 1999, 'The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4', Clinical Cancer Research, vol. 5, no. 12, pp. 4279-4286.
Kubo, Akihito ; Nakagawa, Kazuhiko ; Varma, Ravi K. ; Conrad, Nicholas K. ; Cheng, Jin Quan ; Lee, Wen Ching ; Testa, Joseph R. ; Johnson, Bruce E. ; Kaye, Frederic J. ; Kelley, Michael J. / The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 12. pp. 4279-4286.
@article{838cb24ec94e4d70a40d7219b72752de,
title = "The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4",
abstract = "Loss of p16 functional activity leading to disruption of the p16/cyclin- dependent kinase (CDK) 4:cyclin D/retinoblastoma pathway is the most common event in human tumorigenesis, suggesting that compounds with CDK4 kinase inhibitory activity may be useful to regulate cancer cell growth. To identify such inhibitors, the 60 cancer cell lines of the National Cancer Institute drug screen panel were examined for p16 alterations (biallelic deletion, intragenic mutations, or absent p16 protein), and the growth-inhibitory activity of more than 50,000 compounds against these 60 cell lines was compared with their p16 status. One compound, 3-amino thioacridone (3-ATA; NSC 680434), whose growth-inhibitory activity correlated with the p16 status of the cell lines had an IC50 of 3.1 μM in a CDK4 kinase assay. In addition, four compounds structurally related to 3-ATA inhibited CDK4 kinase with IC50s ranging from 0.2-2.0 μM. All five of these compounds were less potent inhibitors of cell division cycle 2 and CDK2 kinases, with IC50s 30- to 500-fold higher than that for CDK4. ATP competition experiments demonstrated a noncompetitive mode of inhibition for 3-ATA (K(i) = 5.5 μM) and a linear mixed mode for benzothiadiazine (NSC 645787; K(i) = 0.73 μM). We have successfully demonstrated a novel approach to identify specific CDK4 kinase inhibitors that may selectively induce growth inhibition of p16- altered tumors.",
author = "Akihito Kubo and Kazuhiko Nakagawa and Varma, {Ravi K.} and Conrad, {Nicholas K.} and Cheng, {Jin Quan} and Lee, {Wen Ching} and Testa, {Joseph R.} and Johnson, {Bruce E.} and Kaye, {Frederic J.} and Kelley, {Michael J.}",
year = "1999",
month = "12",
language = "English (US)",
volume = "5",
pages = "4279--4286",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4

AU - Kubo, Akihito

AU - Nakagawa, Kazuhiko

AU - Varma, Ravi K.

AU - Conrad, Nicholas K.

AU - Cheng, Jin Quan

AU - Lee, Wen Ching

AU - Testa, Joseph R.

AU - Johnson, Bruce E.

AU - Kaye, Frederic J.

AU - Kelley, Michael J.

PY - 1999/12

Y1 - 1999/12

N2 - Loss of p16 functional activity leading to disruption of the p16/cyclin- dependent kinase (CDK) 4:cyclin D/retinoblastoma pathway is the most common event in human tumorigenesis, suggesting that compounds with CDK4 kinase inhibitory activity may be useful to regulate cancer cell growth. To identify such inhibitors, the 60 cancer cell lines of the National Cancer Institute drug screen panel were examined for p16 alterations (biallelic deletion, intragenic mutations, or absent p16 protein), and the growth-inhibitory activity of more than 50,000 compounds against these 60 cell lines was compared with their p16 status. One compound, 3-amino thioacridone (3-ATA; NSC 680434), whose growth-inhibitory activity correlated with the p16 status of the cell lines had an IC50 of 3.1 μM in a CDK4 kinase assay. In addition, four compounds structurally related to 3-ATA inhibited CDK4 kinase with IC50s ranging from 0.2-2.0 μM. All five of these compounds were less potent inhibitors of cell division cycle 2 and CDK2 kinases, with IC50s 30- to 500-fold higher than that for CDK4. ATP competition experiments demonstrated a noncompetitive mode of inhibition for 3-ATA (K(i) = 5.5 μM) and a linear mixed mode for benzothiadiazine (NSC 645787; K(i) = 0.73 μM). We have successfully demonstrated a novel approach to identify specific CDK4 kinase inhibitors that may selectively induce growth inhibition of p16- altered tumors.

AB - Loss of p16 functional activity leading to disruption of the p16/cyclin- dependent kinase (CDK) 4:cyclin D/retinoblastoma pathway is the most common event in human tumorigenesis, suggesting that compounds with CDK4 kinase inhibitory activity may be useful to regulate cancer cell growth. To identify such inhibitors, the 60 cancer cell lines of the National Cancer Institute drug screen panel were examined for p16 alterations (biallelic deletion, intragenic mutations, or absent p16 protein), and the growth-inhibitory activity of more than 50,000 compounds against these 60 cell lines was compared with their p16 status. One compound, 3-amino thioacridone (3-ATA; NSC 680434), whose growth-inhibitory activity correlated with the p16 status of the cell lines had an IC50 of 3.1 μM in a CDK4 kinase assay. In addition, four compounds structurally related to 3-ATA inhibited CDK4 kinase with IC50s ranging from 0.2-2.0 μM. All five of these compounds were less potent inhibitors of cell division cycle 2 and CDK2 kinases, with IC50s 30- to 500-fold higher than that for CDK4. ATP competition experiments demonstrated a noncompetitive mode of inhibition for 3-ATA (K(i) = 5.5 μM) and a linear mixed mode for benzothiadiazine (NSC 645787; K(i) = 0.73 μM). We have successfully demonstrated a novel approach to identify specific CDK4 kinase inhibitors that may selectively induce growth inhibition of p16- altered tumors.

UR - http://www.scopus.com/inward/record.url?scp=0033386504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033386504&partnerID=8YFLogxK

M3 - Article

C2 - 10632371

AN - SCOPUS:0033386504

VL - 5

SP - 4279

EP - 4286

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -